1)Jin-Qing Liu, Ali Jabbari, Cho-Hao Lin, Venu Akkanapally, Wendy L Frankel, Sujit Basu, Kai He, Pan Zheng,Yang Liu,Xue-Feng Bai(2024)IL-27 Gene Therapy Ameliorates IPEX Syndrome Caused by Germline Mutation of Foxp3 Gene: A Major Role for Induction of IL-10.J Immunol213 (5), 559-566.
2)Zhu J, Yu J, Hu A, Liu JQ, Pan X, Xin G, Carson WE, Li Z, Yang Y,Bai XF. (2023) IL-27 gene therapy inducesstat3-mediated expansion of CD11b+Gr1+myeloid cells and promotes accumulation of M1 macrophagesin the tumor microenvironment.J Immunol211(5):895-902.
3)Jin-Qing Liu, Chengxiang Zhang, Xinfu Zhang, Jingyue Yan, Chunxi Zeng, Fatemeh Talebian, Kimberly Lynch,Weiyu Zhao, Xucheng Hou, Shi Du, Diana D. Kang, Binbin Deng, David W.McComb,Xue-Feng Bai, YizhouDong. (2022) Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancerimmunotherapy.Journal of Controlled Release345: 306-313.
4)Aiyan Hu, Jianmin Zhu, Chunxi Zeng, Cho-Hao Lin, Jianyu Yu, Jin-Qing Liu, Kimberly Lynch, FatemehTalebian, Xueliang Pan, Jingyue Yan, Yizhou Dong, Zihai Li andXue-Feng Bai. (2022) IL-27 induces CCL5production by T lymphocytes which contributes to anti-tumor activity.J Immunol, 208: 2239-2245.
5)Fouad Choueiry, Molly Torok, Reena Shakya, Kriti Agrawal, Anna Deems, Brooke Benner, Alice Hinton,Jami Shaffer, Bradley W Blaser, Anne M Noonan, Terence M Williams, Mary Dillhoff, Darwin L Conwell,Phil A Hart, Zobeida Cruz-Monserrate,Xue-Feng Bai, William E Carson III, Thomas A Mace (2020) CD200promotes immunosuppression in the pancreatic tumor microenvironment.Journal for immunotherapy ofcancer8 (1).
6)Zhu J, Liu JQ, Shi M, Cheng X, Ding M, Zhang J, Davis JP, Varikuti S, Satoskar AR, Lu L, Pan X, Zheng P, Liu Y,Bai XF.(2018) IL-27 gene therapy induces depletion of regulatory T cells and enhances the efficacy ofcancer immunotherapy.JCI InsightApr 5;3(7).pii: 98745. doi: 10.1172/jci.insight.98745. PMID:29618655
7)Liu JQ, Talebian F, Wu L, Liu Z, Li MS, Wu L, Carson WE, Basu S,Bai XF. (2016) A critical role for CD200Rsignaling in limiting the growth and metastasis of CD200-positive melanoma.J Immunol197(4):1489-97.
8)Chu J, He S, Deng Y, Zhang J, Peng Y, Hughes T, Yi L, Kwon CH, Wang QE, Devine S, He X,Bai XF, HofmeisterCC, Yu J. (2014) Genetic Modification of T Cells Redirected towards CS1 Enhances Eradication of MyelomaCells.Clin Cancer Res20(15):3989-4000.
9)Liu Z, Liu JQ, Talebian F, Wu LC, Li S,Bai XF. (2013) IL-27 enhances the survival of tumor antigen-specificCD8+T cells and programs them into IL-10-producing, memory precursor-like effector cells.Eur J Immunol43: 468-479.
10)Wang Z, Liu JQ, Liu Z, Shen R, Zhang G, Xu J, Basu S, Feng Y,Bai XF. (2013) Tumor-Derived IL-35 PromotesTumor Growth by Enhancing Myeloid Cell Accumulation and Angiogenesis.J Immunol190: 2415-2423.
11)Liu JQ, Liu Z, Zhang X, Shi Y, Talebian F, Carl JW Jr, Yu C, Shi FD, Whitacre CC, Trgovcich J,Bai XF(2012) Increased Th17 and Regulatory T Cell Responses in EBV-Induced Gene 3-Deficient Mice Lead to Marginally Enhanced Development of Autoimmune Encephalomyelitis.J Immunol188:3099-3106.
12)Chen GY, Chen X, King S, Cavassani KA, Cheng J, Zheng X, Cao H, Yu H, Qu J, Fang D, Wu W,Bai XF, Liu JQ, Woodiga SA, Chen C, Sun L, Hogaboam CM, Kunkel SL, Zheng P, Liu Y. (2011) Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction.Nat Biotechnol29(5):428-35
13)Liu JQ, Joshi PS, Wang C, El-Omrani HY, Xiao Y, Liu X, Hagan JP, Liu LG, Wu LC,Bai XF. (2010) Targeting activation-induced cytidine deaminase overcomes tumor evasion of immunotherapy by CTLs.J Immunol184(10):5435-43
14)Carl JW, Liu JQ, Joshi PS, El-Omrani HY, Yin L, Zheng X, Whitacre CC, Liu Y,Bai XF. (2008) Autoreactive T cells escape clonal deletion in the thymus by a CD24-dependent pathway.J Immunol181(1):320-8.
15)Bai XF, Liu JQ, Joshi PS, Wang L, Yin L, Labanowska J, Heerema N, Zheng P, Liu Y. (2006) Different lineages of P1A-expressing cancer cells use divergent modes of immune evasion for T-cell adoptive therapy.Cancer Res66(16):8241-9.
16)Bai XF, Li O, Zhou Q, Zhang H, Joshi PS, Zheng X, Liu Y, Wang Y, Zheng P, Liu Y. (2004) CD24 controls expansion and persistence of autoreactive T cells in the central nervous system during experimental autoimmune encephalomyelitis.J Exp Med200(4):447-58.
17)Bai XF, Liu J, Li O, Zheng P, Liu Y. (2003) Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes.J Clin Invest111(10):1487-96.
18)Bai XF, Liu J, May KF, Guo Y, Zheng P, Liu Y. (2002) B7-CTLA4 interaction promotes cognate destruction of tumor cells by cytotoxic T lymphocytes in vivo.Blood99(8):2880-9
19)Bai XF,Gao JX, Liu J, Wen J, Zheng P, Liu Y. (2001) On the site and mode of antigen presentation for theinitiation of clonal expansion of CD8 T cells specific for a natural tumor antigen.Cancer Res61(18):6860.
20)Bai XF, Liu JQ, Liu X, Guo Y, Cox K, Wen J, Zheng P, Liu Y. (2000) The heat-stable antigen determinespathogenicity of self-reactive T cells in experimental autoimmune encephalomyelitis.J ClinInvest105(9):1227-32.
1)Yizhou Dong,Xue-Feng Bai, Jin-Qing Liu, C Zhang, X Zhang (2025). DIAMINO LIPID (DAL) COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS INCLUDING mRNA ENCODING AN IMMUNOTHERAPEUTIC AGENT. US patent App: 18/716,721
2)Xue-Feng Bai, Yizhou Dong, Jin-Qing Liu (2025) CCL5 MRNA NANOPARTICLE AND METHODS OF USE THEREOF. US patent App: 18/844,596
3)XF Bai, Y Liu, P Zheng, Liu Jin-Qing (2019) Immunotherapeutics for cancer and autoimmune diseases. US Patent App. 15/525,013
4)Y Liu, P Zhang,XF Bai(2013) Methods of blocking tissue destruction by autoreactive t cells. US Patent App. 13/886,061
5)Y Liu, P Zheng,X Bai(2010) Method of treating multiple sclerosis and related t-cell initiated tissue destruction by administering HSA/CD24. US Patent 7,744,894
